NCT05005403 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05005403
Title	Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	AbbVie
Indications	gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma triple-receptor negative breast cancer pancreatic adenocarcinoma colorectal cancer gastric adenocarcinoma ovarian serous carcinoma lung non-small cell carcinoma
Therapies	ABBV-514 + Budigalimab ABBV-514 ABBV-514 + Bevacizumab
Age Groups:	senior \| adult
Covered Countries	USA \| ISR

Additional content available in CKB BOOST